Sun Pharma Q2 profit falls 36.4% on one-time charges of Rs 1,269 crore
Sun Pharma's Q2 net profit fell 36.4% to Rs 1,988.53 crore while revenue rose 11.9%, with about Rs 1,269 crore of one-time charges hitting results.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Sun Pharma posted a second-quarter net profit of Rs 1,988.53 crore, down 36.4% year on year, while consolidated revenue rose 11.9% to Rs 16,198.71 crore. According to TradingView, the drop in profit reflects one-time charges of about Rs 1,269 crore: Rs 923 crore for a settlement in a US antitrust case over generic drug pricing, and Rs 346 crore of expenses linked to the proposed Organon deal.
Sales of formulations in India climbed 17.3% to Rs 5,552.3 crore, accounting for 34.5% of revenue. Global innovative medicines brought in about $356 million, up 6.9%, making up 21.1% of the total. Ilumya, Ciqua and Odumzo were the main contributors.
why it matters
For investors, the key question is how much the one-time nature of these costs distorts the picture; without them, profit trends would look considerably better. The TradingView summary is labeled as AI-generated and may contain inaccuracies, so important figures should be checked against original company filings.
market impact
Sun Pharma shares: one-time charges weigh on quarterly profit, while India sales growth gives support
- Sun Pharma shares pressure down — one-time settlement and deal costs cut net profit by 36.4%
tags
instruments
sources
- Key facts: NSE:SUNPHARMA Q2 profit -36.4%; India sales +17.3%; Rs1,269cr — TradingView, 2 November 2026 at 02:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗